AtriCure, Inc.: management transactions · United States · SEC (Form 4)

About AtriCure, Inc.

AtriCure, Inc. is a U.S.-based medical device company listed on the NASDAQ under the ticker ATRC, with its headquarters in Mason, Ohio, United States. The company focuses on surgical therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain control. In practical terms, AtriCure operates as a specialized cardiac and thoracic surgery franchise, selling to hospitals, cardiac surgeons, and care teams that treat complex arrhythmia and pain-management cases. ([news.atricure.com](https://news.atricure.com/press-release?utm_source=openai)) Founded in 2000, AtriCure was built around a clear clinical thesis: improve outcomes in Afib surgery and related procedures through purpose-built tools rather than generic surgical instruments. Over time, the company expanded from core ablation technologies into LAA exclusion and cryoanalgesia, creating a broader portfolio for both open and minimally invasive procedures. Its positioning reflects a niche med-tech innovator with a strong cardiology identity and a growing footprint in perioperative pain management. ([ir.atricure.com](https://ir.atricure.com/news-releases/news-release-details/atricure-announces-us-launch-atriclipr-provtm-device?utm_source=openai)) AtriCure’s main product lines include ablation systems, surgical clamps, LAA exclusion devices, and cryo nerve block solutions. Within its cardiac portfolio, the AtriClip family is a key franchise for LAA management, while the Isolator and EnCompass platforms support surgical ablation workflows. The company also emphasizes cryo-based pain-management tools as a non-opioid option for post-operative pain, including applications in major surgeries where pain control and reduced opioid exposure are important clinical goals. This diversified but still focused product mix helps AtriCure address adjacent needs within the same operating room and specialist customer base. ([atricure.com](https://www.atricure.com/)) From a competitive standpoint, AtriCure benefits from being a recognized specialist in a relatively concentrated segment, where clinical evidence, surgeon familiarity, and product performance matter more than broad catalog breadth. The company highlights guideline-supported LAA exclusion and continued adoption of newer products such as AtriClip FLEX-Mini, cryoSPHERE MAX, and EnCompass, which have supported recent commercial momentum. Geographically, AtriCure sells in the United States and internationally, with management citing both U.S. and global growth in recent reporting periods. ([ir.atricure.com](https://ir.atricure.com/news-releases/news-release-details/atricure-reports-fourth-quarter-2025-and-full-year-2025?utm_source=openai)) Recent operating updates underline the growth profile. AtriCure reported first-quarter 2026 worldwide revenue of $141.2 million, up 14.3% year over year, following full-year 2025 revenue of $534.5 million, up 14.9%. The company has also highlighted new-product adoption and, in late 2025, announced first patient treatments on a novel dual-energy platform. For investors, AtriCure represents a specialized growth med-tech name on the NASDAQ in the United States, with exposure to structural demand in Afib treatment, stroke-risk reduction, and non-opioid pain management. ([ir.atricure.com](https://ir.atricure.com/news-releases/news-release-details/atricure-reports-fourth-quarter-2025-and-full-year-2025?utm_source=openai))